9-[2-(3-indolyl)ethyl-]-1-oxa-4,9-diazaspiro[5.5] undecan-3-one | 83090-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-[2-(3-indolyl)ethyl-]-1-oxa-4,9-diazaspiro[5.5] undecan-3-one
• 英文别名: 9-[2-(3-Indolyl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one；9-[2-(1H-indol-3-yl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
• CAS: 83090-47-5
• 化学式: C₁₈H₂₃N₃O₂
• 分子量: 313.4
• InChiKey: SPALXTYNFFFDEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(2-溴乙基)吲哚 、 3-oxo-1-oxa-4,9-diaza-spiro[5.5]undecane hydrobromide 在 三乙胺 作用下， 以 N-甲基乙酰胺 、 水 为溶剂， 生成 9-[2-(3-indolyl)ethyl-]-1-oxa-4,9-diazaspiro[5.5] undecan-3-one
  参考文献：
  名称：

  9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones

  摘要：

  用于预防和/或治疗高血压、充血性心力衰竭、心律失常、偏头痛、血管痉挛性疾病和哮喘的化合物由以下公式表示##STR1##其中：R、R.sup.1、R.sup.2、R.sup.3和R.sup.4分别独立表示氢或含有一至四个碳原子的较低烷基；R.sup.5和R.sup.6分别独立表示氢、含有一至四个碳原子的较低烷基或含有一至四个碳原子的较低烷氧基；以及其药用可接受的酸盐。

  公开号：

  US04332804A1

文献信息

• 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
  申请人：Syntex (U.S.A.) Inc.

  公开号：US04332804A1

  公开（公告）日：1982-06-01

  Compounds useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma are represented by the formula ##STR1## wherein: R, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently hydrogen or lower alkyl of one to four carbon atoms; and R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms; and the pharmaceutically acceptable acid addition salts thereof.

  用于预防和/或治疗高血压、充血性心力衰竭、心律失常、偏头痛、血管痉挛性疾病和哮喘的化合物由以下公式表示##STR1##其中：R、R.sup.1、R.sup.2、R.sup.3和R.sup.4分别独立表示氢或含有一至四个碳原子的较低烷基；R.sup.5和R.sup.6分别独立表示氢、含有一至四个碳原子的较低烷基或含有一至四个碳原子的较低烷氧基；以及其药用可接受的酸盐。
• 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0061333A1

  公开（公告）日：1982-09-29

  Compounds useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma are represented by the formula wherein: R, R1, R2, R3, and R4 are independently hydrogen or lower alkyl of one to four carbon atoms; and R5 and R6 are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms; and the pharmaceutically acceptable acid addition salts thereof.

  用于预防和/或治疗高血压、充血性心力衰竭、心律失常、偏头痛、血管痉挛性疾病和哮喘的化合物由式表示 其中 R、R1、R2、R3 和 R4 独立地为氢或一至四个碳原子的低级烷基；以及 R5 和 R6 独立地是氢、一至四个碳原子的低级烷基或一至四个碳原子的低级烷氧基；以及 其药学上可接受的酸加成盐。
• JPS57169485A
  申请人：——

  公开号：JPS57169485A

  公开（公告）日：1982-10-19
• US4332804A
  申请人：——

  公开号：US4332804A

  公开（公告）日：1982-06-01
• Antihypertensive 9-substituted 1-0xa-4,9-diazaspiro[5.5]undecan-3-ones
  作者：Robin D. Clark、Joan M. Caroon、David B. Repke、Arthur M. Strosberg、Susan M. Bitter、Marlys D. Okada、Anton D. Michel、Roger L. Whiting

  DOI：10.1021/jm00360a013

  日期：1983.6

  Forty-one 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones were prepared for antihypertensive screening in the spontaneously hypertensive rat (SHR). For the 9-(2-indol-3-ylethyl) series, the parent compound, 9-(2-indol-3-ylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (21), was the most potent antihypertensive agent. Substitution of lower alkyl groups on the spirolactam ring gave compounds close in activity to 21, while substitution with large alkyl or aryl groups led to a significant decrease in activity. Ring-opened analogues of 21 that contained the same functionality were markedly less active. Several 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones substituted at the 9 position with 1,4-benzodioxan-2-ylmethyl, 1,4-benzodioxan-2-ylhydroxyethyl, and 2-phenylethyl groups also demonstrated significant activity. Compound 21 was chosen for a detailed pharmacological evaluation. Its antihypertensive activity appears to be predominantly due to peripheral alpha 1-adrenoceptor blockade.